ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions
  • Abstract Number: 0367

    Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus
  • Abstract Number: 0368

    Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
  • Abstract Number: 0369

    Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis
  • Abstract Number: 0370

    Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
  • Abstract Number: 0371

    Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program
  • Abstract Number: 0372

    Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases
  • Abstract Number: 0373

    Implementation of a Lupus Self-Management mHealth App: Using Incentives to Drive Engagement
  • Abstract Number: 0374

    Assessing Attitudes and Barriers to Vaccination in Pediatric Rheumatic
  • Abstract Number: 0375

    Association of Glucocorticoid Toxicity Index Scores with Quality-of-Life and Healthcare Resource Utilization at 6 Months in a Real-World Cohort of Individuals Receiving Glucocorticoids
  • Abstract Number: 0376

    An Internet-Delivered, Arthritis-Tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-Morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-Users
  • Abstract Number: 0377

    New efforts to incorporate patient-reported outcomes into clinical trials for lupus therapeutics
  • Abstract Number: 0378

    Identifying Patterns of Telemedicine Readiness and Digital Health Literacy in Rheumatoid Arthritis Patients: A Latent Class Analysis
  • Abstract Number: 0379

    Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
  • Abstract Number: 0380

    Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
  • Abstract Number: 0381

    Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology